{"id":"https://openalex.org/W4409690487","doi":"https://doi.org/10.1158/1538-7445.am2025-863","title":"Abstract 863: A novel SIRPA based FiCAR T cells therapy targeting TYRP1 to treat melanoma patients","display_name":"Abstract 863: A novel SIRPA based FiCAR T cells therapy targeting TYRP1 to treat melanoma patients","publication_year":2025,"publication_date":"2025-04-21","ids":{"openalex":"https://openalex.org/W4409690487","doi":"https://doi.org/10.1158/1538-7445.am2025-863"},"language":"en","primary_location":{"id":"doi:10.1158/1538-7445.am2025-863","doi":"https://doi.org/10.1158/1538-7445.am2025-863","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1538-7445.am2025-863","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","is_traditional":false,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5053238978","display_name":"Henrik Paavilainen","orcid":"https://orcid.org/0000-0001-9213-0803","observed_orcids":["https://orcid.org/0000-0001-9213-0803"]},"institutions":[{"id":"https://openalex.org/I4210118237","display_name":"Orion Corporation (Finland)","ror":"https://ror.org/0296s4x19","country_code":"FI","type":"company","lineage":["https://openalex.org/I4210118237"]}],"countries":["FI"],"is_corresponding":false,"raw_author_name":"Henrik Paavilainen","raw_affiliation_strings":["Orion Corporation, Turku, Finland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Orion Corporation, Turku, Finland","institution_ids":["https://openalex.org/I4210118237"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5083289715","display_name":"Sakari P\u00f6ysti","orcid":"https://orcid.org/0000-0001-8639-3391","observed_orcids":["https://orcid.org/0000-0001-8639-3391"]},"institutions":[{"id":"https://openalex.org/I4210118237","display_name":"Orion Corporation (Finland)","ror":"https://ror.org/0296s4x19","country_code":"FI","type":"company","lineage":["https://openalex.org/I4210118237"]}],"countries":["FI"],"is_corresponding":false,"raw_author_name":"Sakari P\u00f6ysti","raw_affiliation_strings":["Orion Corporation, Turku, Finland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Orion Corporation, Turku, Finland","institution_ids":["https://openalex.org/I4210118237"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5043096108","display_name":"Veera Nikoskelainen","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210118237","display_name":"Orion Corporation (Finland)","ror":"https://ror.org/0296s4x19","country_code":"FI","type":"company","lineage":["https://openalex.org/I4210118237"]}],"countries":["FI"],"is_corresponding":false,"raw_author_name":"Veera Nikoskelainen","raw_affiliation_strings":["Orion Corporation, Turku, Finland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Orion Corporation, Turku, Finland","institution_ids":["https://openalex.org/I4210118237"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5086284874","display_name":"Marie C. Nyman","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210118237","display_name":"Orion Corporation (Finland)","ror":"https://ror.org/0296s4x19","country_code":"FI","type":"company","lineage":["https://openalex.org/I4210118237"]}],"countries":["FI"],"is_corresponding":false,"raw_author_name":"Marie Nyman","raw_affiliation_strings":["Orion Corporation, Turku, Finland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Orion Corporation, Turku, Finland","institution_ids":["https://openalex.org/I4210118237"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5108235446","display_name":"Anil K. Thotakura","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210118237","display_name":"Orion Corporation (Finland)","ror":"https://ror.org/0296s4x19","country_code":"FI","type":"company","lineage":["https://openalex.org/I4210118237"]}],"countries":["FI"],"is_corresponding":false,"raw_author_name":"Anil K. Thotakura","raw_affiliation_strings":["Orion Corporation, Turku, Finland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Orion Corporation, Turku, Finland","institution_ids":["https://openalex.org/I4210118237"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I4210118237"],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":1,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"85","issue":"8_Supplement_1","first_page":"863","last_page":"863"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11491","display_name":"CAR-T cell therapy research","score":0.9794999957084656,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11491","display_name":"CAR-T cell therapy research","score":0.9794999957084656,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.009999999776482582,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10580","display_name":"Immunotherapy and Immune Responses","score":0.005900000222027302,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/sirpalpha","display_name":"SIRP\u03b1","score":0.6309999823570251},{"id":"https://openalex.org/keywords/trp-1","display_name":"TRP-1","score":0.9269999861717224},{"id":"https://openalex.org/keywords/melanoma","display_name":"melanoma","score":0.8980000019073486},{"id":"https://openalex.org/keywords/car-t-cell-therapy","display_name":"CAR T-cell therapy","score":0.7480000257492065},{"id":"https://openalex.org/keywords/tumor-antigen-targeting","display_name":"tumor antigen targeting","score":0.47600001096725464},{"id":"https://openalex.org/keywords/tonic-signaling","display_name":"tonic signaling","score":0.5950000286102295},{"id":"https://openalex.org/keywords/cytokine-production","display_name":"cytokine production","score":0.6779999732971191},{"id":"https://openalex.org/keywords/tumor-growth-inhibition","display_name":"tumor growth inhibition","score":0.7730000019073486},{"id":"https://openalex.org/keywords/immune-checkpoint-inhibitors","display_name":"immune checkpoint inhibitors","score":0.4959999918937683},{"id":"https://openalex.org/keywords/braf-mutation","display_name":"BRAF mutation","score":0.5149999856948853},{"id":"https://openalex.org/keywords/tumor-mutational-burden","display_name":"tumor mutational burden","score":0.6039999723434448},{"id":"https://openalex.org/keywords/nsg-mouse-xenograft","display_name":"NSG mouse xenograft","score":0.6159999966621399},{"id":"https://openalex.org/keywords/adoptive-t-cell-therapy","display_name":"adoptive T cell therapy","score":0.5580000281333923}],"concepts":[{"id":"https://openalex.org/C2777658100","wikidata":"https://www.wikidata.org/wiki/Q180614","display_name":"Melanoma","level":2,"score":0.6845558881759644},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.6437119245529175},{"id":"https://openalex.org/C2781230642","wikidata":"https://www.wikidata.org/wiki/Q492646","display_name":"Targeted therapy","level":3,"score":0.6011804342269897},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.4619271159172058},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.40889737010002136},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.40550002455711365},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.22255587577819824}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1158/1538-7445.am2025-863","doi":"https://doi.org/10.1158/1538-7445.am2025-863","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1538-7445.am2025-863","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":1.0}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4401812168","https://openalex.org/W3178808548","https://openalex.org/W3155403957","https://openalex.org/W4416446330","https://openalex.org/W4391676834","https://openalex.org/W4404174164","https://openalex.org/W3083707420","https://openalex.org/W3176786809","https://openalex.org/W7212011522","https://openalex.org/W2939261135"],"abstract_inverted_index":{"Abstract":[0],"Background:":[1],"The":[2,269],"first-generation":[3],"immune":[4,47],"checkpoint":[5,48],"inhibitors":[6,49],"anti-PD1/PDL1":[7],"and":[8,50,122,132,156,162,173,182,209,304,354,373],"anti-CTLA-4":[9],"either":[10],"alone":[11],"or":[12],"in":[13,20,70,83,171,174,234,300,348,352,355],"combination":[14],"have":[15,66,75],"shown":[16,67,76,307],"tremendous":[17],"clinical":[18,68],"success":[19,69],"BRAF":[21,51,57,123,374],"wild":[22],"type":[23],"melanoma":[24,39,139,247,368,401],"cancer":[25],"patients.":[26,140],"However,":[27,339],"there":[28],"is":[29],"still":[30],"a":[31,85,97,207,260,274,297],"high":[32],"unmet":[33],"need":[34],"as":[35,111],"great":[36],"proportion":[37],"of":[38,117,197,212,219,237,263,310,342,361,406],"patients":[40,369,402],"relapsed":[41,54,138],"after":[42,55,87,252],"treatment":[43,56,137],"with":[44,186,202,246,259,292],"first":[45,89],"generation":[46],"mutant":[52],"patient":[53],"inhibitors.":[58,375],"Chimeric":[59],"antigen":[60],"receptor":[61],"(CAR)":[62],"expressing":[63,205,294],"T":[64,106,165,200,229,266,288,316,333,364,394],"cells":[65,80,166,201,204,222,248,289,317,323,334,365,395],"hematological":[71],"malignancies,":[72],"recent":[73],"studies":[74],"that":[77,114],"CAR":[78,105,164],"Ts":[79],"were":[81,167,191,223,244,256,318],"detected":[82],"circulation":[84],"decade":[86],"the":[88,118,220,226,233,238,253,278,343,351,407],"CD19":[90],"CART":[91],"cell":[92],"injection.":[93],"Here,":[94],"we":[95],"generated":[96],"novel":[98,390],"SIRPa":[99],"based":[100,178,392],"extracellular":[101],"extension":[102],"TYRP1":[103,112,125,177,198,206,227,239,264,284,286,293,314,331,362,398],"targeting":[104,126,397],"cell,":[107],"here":[108,272],"onwards":[109],"referred":[110],"FiCAR,":[113],"work":[115,282],"independent":[116],"tumor":[119,203,295,322,337],"mutation":[120],"burden":[121],"status.":[124],"FiCARs":[127],"could":[128],"be":[129],"an":[130],"alternative":[131],"attractive":[133],"therapeutic":[134],"strategy":[135],"for":[136,169,277,410],"Methods":[141],"&":[142],"Results:":[143],"A":[144,389],"well-known":[145],"anti-TYRP1":[146],"binder":[147],"flanvotumab\u2019s":[148],"scfv":[149],"was":[150,215,345],"inserted":[151],"into":[152],"FiCAR-structure":[153],"containing":[154],"CD28":[155],"CD3zeta":[157],"intra":[158],"cellular":[159],"signaling":[160],"domain":[161],"those":[163],"studied":[168],"both":[170],"vitro":[172,353],"vivo":[175,235,356],"function.":[176],"FiCAR":[179,199,228,265,279,287,315,332,363,393],"grew":[180],"normally":[181],"good":[183],"transduction":[184],"rates":[185],"low":[187],"vector":[188],"copy":[189],"numbers":[190],"achieved.":[192],"In":[193,329],"addition,":[194],"upon":[195,290],"co-culture":[196,291],"rapid":[208],"significant":[210,298],"release":[211],"pro-inflammatory":[213],"cytokines":[214,302],"detected.":[216],"Moreover,":[217],"killing":[218],"target":[221],"observed":[224],"by":[225],"cells.":[230,267],"To":[231],"study":[232,276],"functionality":[236],"FiCAR-T":[240],"cells,":[241],"NSG":[242],"mice":[243,255],"inoculated":[245],"subcutaneously.":[249],"Three":[250],"weeks":[251],"inoculation":[254],"intravenously":[257],"injected":[258],"single":[261],"dose":[262],"Discussion:":[268],"data":[270,357],"presented":[271],"shows":[273],"proof-of-concept":[275],"structure":[280],"to":[281,320,366,371,399],"against":[283],"antigen.":[285],"elicited":[296],"increase":[299],"effector":[301],"production":[303],"has":[305],"not":[306,346],"any":[308],"signs":[309],"tonic":[311],"signaling.":[312],"Additionally,":[313],"able":[319],"kill":[321],"efficiently":[324],"reaching":[325],"100%":[326],"maximal":[327],"killing.":[328],"vivo,":[330],"significantly":[335],"delayed":[336],"growth.":[338],"full":[340],"regression":[341],"tumors":[344],"achieved":[347],"vivo.":[349],"Collectively,":[350],"support":[358],"further":[359],"optimization":[360],"treat":[367,400],"refractory":[370],"immunotherapy":[372],"Citation":[376],"Format:":[377],"Henrik":[378],"Paavilainen,":[379],"Sakari":[380],"P\u00f6ysti,":[381],"Veera":[382],"Nikoskelainen,":[383],"Marie":[384],"Nyman,":[385],"Anil":[386],"K.":[387],"Thotakura.":[388],"SIRPA":[391],"therapy":[396],"[abstract].":[403],"In:":[404],"Proceedings":[405],"American":[408],"Association":[409],"Cancer":[411,428],"Research":[412],"Annual":[413],"Meeting":[414],"2025;":[415],"Part":[416],"1":[417],"(Regular":[418],"Abstracts);":[419],"2025":[420],"Apr":[421],"25-30;":[422],"Chicago,":[423],"IL.":[424],"Philadelphia":[425],"(PA):":[426],"AACR;":[427],"Res":[429],"2025;85(8_Suppl_1):Abstract":[430],"nr":[431],"863.":[432]},"counts_by_year":[{"year":2025,"cited_by_count":1}],"updated_date":"2026-09-22T06:50:58.402377","created_date":"2025-04-23T00:00:00"}